Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.
Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...
Zacks.com on MSN2h
SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer StudySanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...
Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...
Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).
Daratumumab therapy resulted in superior progression-free survival in frail patients with previously untreated multiple myeloma.
Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...
A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies. Click here to find out why I ...
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaSarclisa SC formulation added to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback